

Product datasheet for AR31148PU-N

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

VEGF-A (Isoform 145) Human Protein

Product data:

Product Type: Recombinant Proteins

Description: VEGF-A (Isoform 145) human recombinant protein, 20 μg

Species: Human
Expression Host: E. coli

Expression cDNA Clone

or AA Sequence:

APMAEGGGQN HHEVVKFMDV YQRSYCHPIE TLVDIFQEYP DEIEYIFKPS CVPLMRCGGC

CNDEGLECVP TEESNITMQI MRIKPHQGQH IGEMSFLQHN KCECRPKKDR ARQEKKSVRG

KGKGQKRKRK KSRYKSWSVC DKPRR

Predicted MW: 34 kDa

Purity: >95% by SDS-PAGE and visualised by silver stain

Buffer: Presentation State: Purified

State: Lyophilized puirified protein Buffer System: 50 mM Acetic Acid

Preservative: None Stabilizer: None

Biological: The ED50 for stimulation of 3H-thymidine incorporation and cell proliferation by

human umbilical vein endothelial cells for VEGF145 has been determined to be in the range

of 10 ng/ml.

Endotoxin: < 0.1 ng per µg of VEGF145

Reconstitution Method: Restore in water to a concentration not lower than 50 µg/ml.

For long term storage we recommend to add at least 0.1% Human or Bovine Serum Albumin.

Preparation: Lyophilized puirified protein

Protein Description: Recombinant Human VEGF145.

Result by N-terminal sequencing: APMAEGG

Note: Centrifuge vials before opening!

Storage: Store lyophilized at 2-8°C for 6 months or at -20°C long term.

After reconstitution store the antibody undiluted at 2-8°C for one month

or (in aliquots) at -20°C long term. Avoid repeated freezing and thawing.

Stability: Shelf life: one year from despatch.





VEGF-A (Isoform 145) Human Protein - AR31148PU-N

RefSeq: NP 001020537

 Locus ID:
 7422

 UniProt ID:
 P15692

 Cytogenetics:
 6p21.1

Synonyms: MVCD1; VEGF; VPF

Summary: This gene is a member of the PDGF/VEGF growth factor family. It encodes a heparin-binding

protein, which exists as a disulfide-linked homodimer. This growth factor induces proliferation and migration of vascular endothelial cells, and is essential for both physiological and pathological angiogenesis. Disruption of this gene in mice resulted in abnormal embryonic blood vessel formation. This gene is upregulated in many known tumors and its expression is correlated with tumor stage and progression. Elevated levels of this protein are found in patients with POEMS syndrome, also known as Crow-Fukase syndrome. Allelic variants of this gene have been associated with microvascular complications of diabetes 1 (MVCD1) and atherosclerosis. Alternatively spliced transcript variants encoding different isoforms have been described. There is also evidence for alternative translation initiation from upstream non-AUG (CUG) codons resulting in additional isoforms. A recent study showed that a C-terminally extended isoform is produced by use of an alternative inframe translation termination codon via a stop codon readthrough mechanism, and that this isoform is antiangiogenic. Expression of some isoforms derived from the AUG start codon is regulated by a small upstream open reading frame, which is located within an internal ribosome entry site. The levels of VEGF are increased during infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), thus promoting inflammation by facilitating recruitment of inflammatory cells, and by increasing the level of angiopoietin II (Ang II), one of two products of the SARS-CoV-2 binding target, angiotensin-converting

in the release of inflammatory cytokines. [provided by RefSeq, Jun 2020]

Protein Families: Druggable Genome, Secreted Protein

Protein Pathways: Bladder cancer, Cytokine-cytokine receptor interaction, Focal adhesion, mTOR signaling

pathway, Pancreatic cancer, Pathways in cancer, Renal cell carcinoma, VEGF signaling

enzyme 2 (ACE2). In turn, Ang II facilitates the elevation of VEGF, thus forming a vicious cycle

pathway



Product images:

